UK markets open in 1 hour 4 minutes

Inventiva S.A. (0RNK.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
7.62-4.34 (-36.29%)
At close: 05:48PM GMT
Full screen
Previous close11.96
Open11.66
Bid0.00 x N/A
Ask0.00 x N/A
Day's range11.60 - 11.66
52-week range11.60 - 11.66
Volume662
Avg. volumeN/A
Market cap144.867M
Beta (5Y monthly)0.89
PE ratio (TTM)N/A
EPS (TTM)-1.21
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Inventiva reports 2021 Third Quarter Financial Information

    Cash and cash equivalents at €105.7m as of September 30, 2021Revenues of €0.2m for the first nine months of 2021 Daix (France), Long Island City (New York, United States), November 10, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today reported it

  • Globe Newswire

    Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021

    Presentation of five scientific abstracts selected for poster presentations at the AASLD The Liver Meeting™ 2021 by Prof. Nezam Afdhal and Prof. Jörn SchattenbergUpdate on the current NASH landscape by Prof. Nezam AfdhalUpdate on Inventiva’s Phase II clinical trial evaluating lanifibranor in patients with type 2 diabetes (T2D) and non alcoholic fatty liver disease (NAFLD) by Prof. Kenneth CusiPresentation of Inventiva’s Phase IIa combination study with lanifibranor and SGLT2 inhibitor empagliflo

  • Globe Newswire

    Inventiva announces participation at several conferences in November 2021

    Daix (France), Long Island City (New York, United States), November 29, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company’s leadership will participate in two upcoming conferences in November 2021. The event details are